Wounds and Injuries

All Conditions

Neoplasms

Rare Diseases

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Pre-operative IMRT with concurrent and sequential Anlotinib

Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT

Anlotinib hydrochloride

Ning-Ning Lu

Ningning Lu, Doctor

Shu-Lian Wang, M.D.

Shu-Lian Wang, M.D

Sheng-Ji Yu, M.D

Ning-Ning Lu, M.D.

To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma

Preoperative Intensity-modulated Radiotherapy (IMRT) With Concurrent Anlotinib Hydrochloride for Localised Extremity or Trunk Sarcoma

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Evaluate quality of life by QOL questionnaires at different time points

Evaluate quality of life by MSTS forms at different time points

evaluate the tumor remission rate microscopically

Chinese Academy of Medical Sciences

Principle Investigator

Antineoplastic Agents

All Drugs and Chemicals

Apatinib

Protein Kinase Inhibitors

Enzyme Inhibitors

Apatinib 500mg QD, used 2 weeks prior to IMRT, concurrent with pre-operative IMRT, and 1 month after end of IMRT

Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT

Apatinib Mesylate

To investigate the safety and efficacy of preoperative IMRT and concurrent Apatinib for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Apatinib for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma

Preoperative Intensity-modulated Radiotherapy (IMRT) With Concurrent Apatinib Mesylate for Localised Extremity or Trunk Sarcoma

Evaluate the quality of life by patient-reported EORTC-QLQ-C30 questionnaire at different time points

Evaluate the extremity function by MSTS (Musculoskeletal Tumor Rating Scale) and TESS (Toronto Extremity Salvage Score) forms at different time points

Evaluate the tumor remission rate microscopically 2 weeks after operation

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma	NCT05167994	Sarcoma,Soft Ti... Extremity Trunk Anlotinib Intensity-modul... Major Wound Com...	Anlotinib hydro...	18 Years -	ChineseAMS
Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma	NCT05235100	Sarcoma,Soft Ti... Extremity Trunk Intensity-modul... Targetd Therapy Major Wound Com...	Apatinib Mesyla...	18 Years -	ChineseAMS
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma	NCT05167994	Sarcoma,Soft Ti... Extremity Trunk Anlotinib Intensity-modul... Major Wound Com...	Anlotinib hydro...	18 Years -	ChineseAMS

Spots Global Cancer Trial Database for major wound complications